ArticleScience translational medicine2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.
Abstract read
In one paragraph
Article in Science translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors.Science advances · 2026Article
- Targeting KRAS reprograms a Treg-dominant immunosuppressive microenvironment and sensitizes KRAS-mutant gastric adenocarcinoma to CTLA-4 immunotherapy.Science China. Life sciences · 2026Article
- Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Synthesis and Biochemical Characterization of Investigational Pyrazolopyrimidine-Based Allosteric KRAS Modulators.ACS medicinal chemistry letters · 2026Article
- KRAS-driven immune exclusion in pancreatic ductal adenocarcinoma: mechanisms and therapeutic reversal.The oncologist · 2026Review
- Comprehensive review of current management and precision medicine in pancreatic cancer.Journal of the Chinese Medical Association : JCMA · 2026Review
- KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.Frontiers in oncology · 2026Review
- Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- RAS signaling and remodeling of the immune microenvironment in pancreatic ductal adenocarcinoma: implications of emerging RAS-targeted therapy.Frontiers in cell and developmental biology · 2026Review
- Key Considerations for TargetingDrug design, development and therapy · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Kathleen M McAndrewsUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-4092-4991
Francesca ParadisoUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Clint A StalneckerDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-0570-4416
Benson S ChellakkanUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-8013-1294
Fredrik I ThegeUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-1822-4526
David H PengUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-0511-1888
Barbara A Moreno DiazUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hikaru SugimotoUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sarah I PatelUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Krishnan K MahadevanUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6503-6851
Michelle L KirtleyUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Danielle WillsUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Amari M SockwellUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0009-0008-1963-4181
Andre Luis F FonsecaUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-1821-0749
Yunhe LiuUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2120-952X
Kimal I RajapaksheUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-0472-858X
Nathaniel G YeeUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0009-0007-0825-7520
Phuong Thao TranUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Huda Alchikh OmarUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Antonio TedeschiBoehringer Ingelheim RCV GmbH & Co KG, Vienna 1121, Austria.ORCID 0000-0001-7276-4550
Fiorella Schischlik-SieglBoehringer Ingelheim RCV GmbH & Co KG, Vienna 1121, Austria.
Andrew S BoghossianBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-7008-8138
Matthew G ReesBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-2987-7581
Melissa M RonanBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0003-4269-1404
Jennifer A RothBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-5117-5586
Dorothea RudolphBoehringer Ingelheim RCV GmbH & Co KG, Vienna 1121, Austria.
Martin AichingerBoehringer Ingelheim RCV GmbH & Co KG, Vienna 1121, Austria.ORCID 0009-0000-2708-1689
Florian EbnerBoehringer Ingelheim RCV GmbH & Co KG, Vienna 1121, Austria.ORCID 0000-0003-1372-8837
Artem V ArtemovBoehringer Ingelheim RCV GmbH & Co KG, Vienna 1121, Austria.
Jesse LippBoehringer Ingelheim RCV GmbH & Co KG, Vienna 1121, Austria.ORCID 0009-0005-5211-7264
Laura PisarskyBoehringer Ingelheim RCV GmbH & Co KG, Vienna 1121, Austria.ORCID 0000-0002-5585-9221
Valerie Laura HerrmannBoehringer Ingelheim Pharma GmbH & Co KG, Biberach 88937, Germany.ORCID 0009-0006-9359-5032
John ParkBoehringer Ingelheim Pharma GmbH & Co KG, Biberach 88937, Germany.ORCID 0000-0002-5674-6026
Jörg F RippmannBoehringer Ingelheim Pharma GmbH & Co KG, Biberach 88937, Germany.ORCID 0000-0002-6666-6222
Otmar SchaafBoehringer Ingelheim RCV GmbH & Co KG, Vienna 1121, Austria.
Vanessa ChandlerUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mariah WilliamsUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0009-0005-3958-0369
Charles E DeckardUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Linghua WangUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-9380-0266
Channing J DerDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-7751-2747
Christopher VellanoUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6643-0818
Paola A GuerreroUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-7345-1246
Timothy P HeffernanUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-3166-8922
Raghu KalluriUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2190-547X
Anirban MaitraUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7923-9978
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2006 to 2025
$41.7MWashington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9MProject 4: The role of codon bias in RAS tumorigenesisP01CA203657 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 2016 to 2020
$7.9MTargeting undruggable RAS for cancer treatmentR35CA232113 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 2018 to 2024
$6.3MBIOLOGICAL ACTIVITY OF RAS ONCOGENESR01CA042978 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1986 to 2017
$5.9MIdentification of synthetic lethal interactors in pancreatic cancerU01CA199235 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COX, ADRIENNE D, DER, CHANNING J. · 2015 to 2019
$2.5MMechanisms of PAK1 activation, signaling and tumor resistanceR01CA175747 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J., HAHN, KLAUS M. · 2014 to 2018
$1.8MTHERMO SCIENTIFIC Q EXACTIVE HF-X HYBRID QUADRUPOLE-ORBITRAP MASS SPECTROMETERS10OD026804 · OD · BAYLOR COLLEGE OF MEDICINE · PI MALOVANNAYA, ANNA · 2019 to 2019
$717kNCI NIH HHS P01 CA117969NCI NIH HHS P01 CA203657NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA196510NCI NIH HHS R01 CA042978NCI NIH HHS R01 CA175747NCI NIH HHS R35 CA232113NCI NIH HHS U01 CA199235NIH HHS S10 OD026804
Abstract
PubMed holds no abstract for this paper.
Indexed as
AllelesMutationPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Signal TransductionAnimalsCarcinoma, Pancreatic DuctalCell Line, TumorHumansMiceTumor MicroenvironmentXenograft Model Antitumor AssaysKRAS protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.